Myelodysplastic Syndrome With Excess Blasts

16 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Myelodysplastic Syndrome With Excess Blasts

Record	Firm	Date
Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCT03399773)	Fred Hutchinson Cancer Center	2022-05-10
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCT03670966)	Fred Hutchinson Cancer Center	2019-07-10
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (NCT03383575)	M.D. Anderson Cancer Center	2018-01-17
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034)	Fred Hutchinson Cancer Center	2017-10-24
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782)	M.D. Anderson Cancer Center	2017-10-13
Personalized NK Cell Therapy in CBT (NCT02727803)	M.D. Anderson Cancer Center	2016-05-19
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD (NCT02220985)	Fred Hutchinson Cancer Center	2015-03-23
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT01522976)	National Cancer Institute (NCI)	2012-03-01
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia (NCT01168219)	National Cancer Institute (NCI)	2010-07-15
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT00801489)	M.D. Anderson Cancer Center	2007-04-04
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia (NCT00392353)	National Cancer Institute (NCI)	2006-11-22
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission (NCT00093470)	National Cancer Institute (NCI)	2004-08-18

Track Myelodysplastic Syndrome With Excess Blasts automatically

Every clearance here is in the API, with alerts when new ones post.